Connor, Clark & Lunn Investment Management Ltd. Xenon Pharmaceuticals Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$33.06 - $39.43 $191,714 - $228,654	5,799 New	5,799 $228,000
Q2 2022 Aug 05, 2022	SELL	$25.44 - $35.16 $194,819 - $269,255	-7,658 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$25.09 - $33.13 $192,139 - $253,709	7,658 New	7,658 $234,000

Others Institutions Holding XENE

# of Institutions

212

Shares Held

70.2M

Call Options Held

88.3K

Put Options Held

28.8K

Avoro Capital Advisors LLC New York, NY

5.67M
Shares

$220 Million
3.36% of portfolio
Driehaus Capital Management LLC Chicago, IL

4.6M
Shares

$179 Million
1.77% of portfolio
Wellington Management Group LLP Boston, MA

3.84M
Shares

$150 Million
0.03% of portfolio
Braidwell LP Stamford, CT

2.71M
Shares

$105 Million
3.02% of portfolio
Commodore Capital LP New York, NY

2.7M
Shares

$105 Million
9.03% of portfolio

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account